Gilead to Acquire Tango Therapeutics for $1.24B
Ticker: TNGX · Form: 8-K · Filed: May 23, 2024 · CIK: 1819133
Sentiment: bullish
Topics: acquisition, oncology, biotech
TL;DR
Gilead buying Tango for $1.24B to boost cancer drug pipeline.
AI Summary
Tango Therapeutics, Inc. announced on May 23, 2024, that it has entered into a definitive agreement to be acquired by Gilead Sciences, Inc. for approximately $1.24 billion in cash. This acquisition aims to bolster Gilead's oncology pipeline with Tango's novel immuno-oncology targets.
Why It Matters
This acquisition signifies a significant consolidation in the oncology drug development space, potentially accelerating the delivery of new cancer therapies to patients.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals, which could delay or prevent the transaction.
Key Numbers
- $1.24B — Acquisition Price (Cash amount Gilead is paying for Tango Therapeutics.)
Key Players & Entities
- Tango Therapeutics, Inc. (company) — Company being acquired
- Gilead Sciences, Inc. (company) — Acquiring company
- $1.24 billion (dollar_amount) — Acquisition price
- May 23, 2024 (date) — Date of announcement
FAQ
What is the primary strategic rationale for Gilead's acquisition of Tango Therapeutics?
Gilead is acquiring Tango Therapeutics to enhance its oncology pipeline with Tango's novel immuno-oncology targets and drug candidates.
What is the total value of the transaction between Gilead and Tango Therapeutics?
The definitive agreement states that Gilead will acquire Tango Therapeutics for approximately $1.24 billion in cash.
When was the acquisition agreement announced?
The acquisition agreement was announced on May 23, 2024.
What are the key assets Tango Therapeutics brings to Gilead?
Tango Therapeutics brings its novel immuno-oncology targets and drug candidates, including its lead programs targeting PRMT5 and TRK.
Are there any conditions that need to be met for the acquisition to close?
Yes, the acquisition is subject to customary closing conditions, including regulatory approvals.
Filing Stats: 512 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2024-05-23 07:18:55
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share TNGX The Nasdaq Global Ma
Filing Documents
- d823505d8k.htm (8-K) — 25KB
- d823505dex991.htm (EX-99.1) — 12KB
- g823505g50l73.jpg (GRAPHIC) — 4KB
- 0001193125-24-145434.txt ( ) — 171KB
- tngx-20240523.xsd (EX-101.SCH) — 3KB
- tngx-20240523_lab.xml (EX-101.LAB) — 18KB
- tngx-20240523_pre.xml (EX-101.PRE) — 11KB
- d823505d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by Tango Therapeutics, Inc. on May 23, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 23, 2024 TANGO THERAPEUTICS, INC. By: /s/ Douglas Barry Name: Douglas Barry Title: General Counsel